SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

ACR-525

ACRV·Acrivon Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2-ready (Phase 1 completed)
Time to market
ACR-525 is Phase 2-ready but has not yet initiated a Phase 2 trial. Assuming successful development, an approval in EoE would likely be several years away (3-5+ years minimum).
Why 3/10
No hard dated binary catalyst (PDUFA or pivotal readout) is scheduled for ACR-525 in the next ~12 months. The asset was just acquired on November 6, 2026, and is Phase 2-ready but has not yet initiated a Phase 2 trial. The next catalysts are a KOL webcast (Nov 10) and Q3 earnings (Nov 12), neither of which is a binary regulatory or pivotal-data event for this drug.
Actionable Insight NEUTRAL

Watch the November 10 KOL webcast for clinical development strategy and the November 12 Q3 earnings call for cash position updates. The undisclosed acquisition cost makes it hard to assess the financial impact on Acrivon's ~$75M market cap company. Any subsequent financing or partnership announcement would be a key signal.

Price Chart

Loading chart...

Executive Summary

ACR-525 is a Phase 2-ready, oral, highly selective JAK1 inhibitor that Acrivon Therapeutics (NASDAQ: ACRV) acquired from Aqilion AB on November 6, 2026, for an undisclosed cash sum with no future milestone or royalty obligations. Formerly known as AQ280, the drug targets eosinophilic esophagitis (EoE) as its first potential indication and marks Acrivon's expansion from precision oncology into immunology and inflammation. The deal closed concurrently with signing and was approved by both companies' boards. Acrivon plans to host a KOL webcast on November 10 to discuss the development plan. At a ~$75M market cap and ~$1.60 stock price, the undisclosed deal cost and early-stage nature of the asset make this a neutral watch item with no near-term binary catalyst.

How It Works

ACR-525 is an oral JAK1 inhibitor. JAK1 is an enzyme that helps transmit inflammatory signals inside cells. By blocking JAK1, the drug aims to reduce the inflammation that drives autoimmune diseases. It is designed to be highly selective for JAK1 over other similar enzymes (JAK2, JAK3, TYK2), which may reduce side effects like anemia or immune suppression that broader JAK inhibitors can cause.

Trial Status

ACR-525 (formerly AQ280) has completed Phase 1 studies and is described as Phase 2-ready. The first targeted indication is eosinophilic esophagitis (EoE), using a formulation designed for patients with difficulty swallowing. No Phase 2 trial has been initiated or registered as of the acquisition date (November 6, 2026).

The Two-Sided Case

▲ Bull Case5
ACR-525 is a Phase 2-ready, oral, highly selective JAK1 inhibitor with a formulation designed for EoE patients who have difficulty swallowing, a clear differentiator.
Acrivon's AP3 platform profiling characterized ACR-525 as having minimal off-target effects compared to approved JAK inhibitors and dupilumab.
The deal includes no future milestone or royalty obligations, giving Acrivon full downstream upside if the drug succeeds.
Expansion into immunology/inflammation opens a large new addressable market beyond oncology, diversifying the pipeline.
Top institutional holder RA Capital Management added 46.6% to its position in Q2 2026, signaling confidence.
▼ Bear Case5
Undisclosed acquisition cost creates uncertainty about cash burn and potential dilution for a ~$75M market cap company.
ACR-525 is Phase 2-ready but has not yet demonstrated efficacy in EoE or any indication; clinical risk remains high.
Acrivon is primarily an oncology company; the pivot into immunology/inflammation requires new expertise and resource allocation away from its core pipeline.
No future milestones or royalties means Acrivon bears 100% of development costs with no partner risk-sharing.
Analyst coverage is stale (last action January 2026), suggesting limited Street attention despite the acquisition.

Upcoming Catalysts

  • November 10, 2026: KOL webcast on ACR-525 development plan and EoE clinical strategy
  • November 12, 2026: ACRV Q3 2026 earnings call (company-level catalyst)
  • Initiation of Phase 2 trial in EoE (date not yet announced)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Acrivon Therapeutics, Inc. 8-K ACRV ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 globenewswire.com3 streetinsider.com4 markets.businessinsider.com